文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

内皮素A和B受体:实验性脓毒症中微循环-线粒体治疗的潜在靶点

Endothelin A and B Receptors: Potential Targets for Microcirculatory-Mitochondrial Therapy in Experimental Sepsis.
PubMed 文献 · Shock · 2020-01-01
一句话结论在大鼠粪性腹膜炎脓毒症模型中,ETA受体拮抗剂与ETB1受体激动剂联用可降低血浆ET-1、改善肠道微循环并逆转线粒体功能障碍。

研究在Sprague Dawley大鼠粪性腹膜炎脓毒症模型中,于诱导后22小时分别给予ETA受体拮抗剂ETR-p1/fl肽(100 nmol/kg静注)、ETB1受体激动剂IRL-1620(0.55 nmol/kg静注)或两者联用,观察90分钟。脓毒症动物表现为低血压、血浆ET-1升高、回肠毛细血管灌注(CPR)和氧摄取(ExO2)及线粒体Complex I/II-linked OXPHOS能力下降。ETR-p1/fl使ExO2升高>45%并改善CPR和CII-linked OXPHOS;IRL-1620使低血压回升>30%、ExO2正常化并增加CPR;联用降低血浆ET-1、改善肠道微循环>41%并逆转线粒体功能障碍。作者认为联合靶向ETA-R和ETB1-R的叠加效应可能为实验性脓毒症提供新的微循环与线粒体复苏策略。

要点

  • 脓毒症大鼠模型诱导后22小时给予ETA-R拮抗剂ETR-p1/fl肽100 nmol/kg静注,使氧摄取(ExO2)升高>45%,并改善回肠毛细血管灌注和CII-linked OXPHOS能力。
  • ETB1-R激动剂IRL-1620 0.55 nmol/kg静注使脓毒症诱导的低血压回升>30%,使ExO2正常化并增加回肠毛细血管灌注。
  • ETA-R拮抗剂与ETB1-R激动剂联用降低血浆ET-1水平、使肠道微循环改善>41%并逆转线粒体功能障碍。
  • 脓毒症动物基线表现为低血压、血浆ET-1升高、回肠CPR与ExO2下降、CI-CII-linked OXPHOS能力降低。
  • 作者认为联合靶向ETA-R和ETB1-R的叠加效应可能为实验性脓毒症提供新的微循环与线粒体复苏策略。

适用人群与场景

  • Sprague Dawley大鼠粪性腹膜炎(0.6 g/kg腹腔注射)脓毒症模型,于诱导后22小时进行干预;另设假手术组。

处置流程与药物剂量

  • ETA-R拮抗剂组:ETR-p1/fl肽100 nmol/kg静脉注射,脓毒症诱导后22小时给药。
  • ETB1-R激动剂组:IRL-1620 0.55 nmol/kg静脉注射,脓毒症诱导后22小时给药。
  • 联合治疗组:ETA-R拮抗剂ETR-p1/fl肽与ETB1-R激动剂IRL-1620联用,脓毒症诱导后22小时给药。
  • 对照:脓毒症动物给予生理盐水。

研究设计与关键结果

  • 研究类型:动物实验(大鼠粪性腹膜炎脓毒症模型),比较生理盐水、ETR-p1/fl肽(100 nmol/kg静注)、IRL-1620(0.55 nmol/kg静注)及联合治疗,观察90分钟。
  • 脓毒症动物表现为低血压、血浆ET-1升高、回肠CPR下降、ExO2下降、CI-CII-linked OXPHOS能力降低。
  • ETR-p1/fl治疗使ExO2升高>45%,并增加CPR和CII-linked OXPHOS能力。
  • IRL-1620使脓毒症诱导的低血压回升>30%,使ExO2正常化并增加CPR。
  • 联合治疗降低血浆ET-1水平,使肠道微循环改善>41%,并逆转线粒体功能障碍。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠脓毒症模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,联合靶向ETA-R和ETB1-R的叠加效应可能为实验性脓毒症提供一种新的微循环与线粒体复苏策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The hypoxia-sensitive endothelin (ET) system plays an important role in circulatory regulation through vasoconstrictor ETA and ETB2 and vasodilator ETB1 receptors. Sepsis progression is associated with microcirculatory and mitochondrial disturbances along with tissue hypoxia. Our aim was to investigate the consequences of treatments with the ETA receptor (ETA-R) antagonist, ETB1 receptor (ETB1-R) agonist, or their combination on oxygen dynamics, mesenteric microcirculation, and mitochondrial respiration in a rodent model of sepsis. Sprague Dawley rats were subjected to fecal peritonitis (0.6 g kg i.p.) or a sham operation. Septic animals were treated with saline or the ETA-R antagonist ETR-p1/fl peptide (100 nmol kg i.v.), the ETB1-R agonist IRL-1620 (0.55 nmol kg i.v.), or a combination therapy 22 h after induction. Invasive hemodynamic monitoring and blood gas analysis were performed during a 90-min observation, plasma ET-1 levels were determined, and intestinal capillary perfusion (CPR) was detected by intravital videomicroscopy. Mitochondrial Complex I (CI)- and CII-linked oxidative phosphorylation (OXPHOS) was evaluated by high-resolution respirometry in liver biopsies. Septic animals were hypotensive with elevated plasma ET-1. The ileal CPR, oxygen extraction (ExO2), and CI-CII-linked OXPHOS capacities decreased. ETR-p1/fl treatment increased ExO2 (by >45%), CPR, and CII-linked OXPHOS capacity. The administration of IRL-1620 countervailed the sepsis-induced hypotension (by >30%), normalized ExO2, and increased CPR. The combined ETA-R antagonist-ETB1-R agonist therapy reduced the plasma ET-1 level, significantly improved the intestinal microcirculation (by >41%), and reversed mitochondrial dysfunction. The additive effects of a combined ETA-R-ETB1-R-targeted therapy may offer a tool for a novel microcirculatory and mitochondrial resuscitation strategy in experimental sepsis.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Rutai A, Fejes R, Juhász L, et al. Endothelin A and B Receptors: Potential Targets for Microcirculatory-Mitochondrial Therapy in Experimental Sepsis. Shock. 2020. PMID: 31318833. doi:10.1097/SHK.0000000000001414

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。